PSTX קפיטליזציה חשבונאית Poseida Therapeutics, Inc.

This daily price chart for Poseida Therapeutics (PSTX) on the GURU.Markets platform is based on the development of cutting-edge treatments for oncology and rare blood pathologies through partnerships with pharma behemoths. The development ecosystem is supported by capital from Sanofi and Roche under strict FDA oversight, and the current metric stands at 0.09. The primary revenue is generated by the licensing of the piggyBac platform for the treatment of solid tumors.

Fundamental asset selection requires analyzing a business's material base through the difference between all company assets and liabilities. This metric measures the value of net assets, which for Poseida Therapeutics (PSTX), amid the expansion of allogeneic CAR-T therapies and partnerships with pharma behemoths, reflects real financial stability as clearly demonstrated by the book capitalization value.